Clinical Trial Update: A Safety, Tolerability and Pharmacokinetic Study of ND0611 on the Top of Different Oral Dosage Forms of Levodopa/Carbidopa in Parkinson's Disease Patients [Phase 1, Phase 2]

View source ↗

Summary

This study evaluated the safety, tolerability, and pharmacokinetics of ND0611 when added to different oral strengths of levodopa/carbidopa in Parkinson's diseas…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• Levodopa/Carbidopa (levodopa/carbidopa)
• ND0611 (ND0611)

Snippet

Sponsor: NeuroDerm Ltd. | Conditions: Parkinson's Disease | Phase 1, Phase 2 | Status: COMPLETED